TARS
Tarsus Pharmaceuticals Inc
74.10$
-0.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.1% | +31.6% | +7.9% | -0.1% | +0.2% | +32.8% | -1.1% | +8.0% | +5.2% | +3.4% | +5.2% | |
| – | -1.2% | +33.0% | +6.4% | -1.5% | -0.1% | +34.8% | -1.3% | +5.7% | +4.2% | +2.8% | +4.6% | |
| – | -0.8% | -13.9% | -6.5% | -2.7% | -46.2% | +85.4% | -45.0% | +16.6% | +62.9% | -44.4% | +100.2% | |
| – | -7.9% | +31.3% | +8.4% | -2.0% | -8.1% | +40.0% | -6.6% | +5.4% | +3.8% | -6.8% | +15.7% | |
| – | +178.1% | +77.0% | -1.7% | -1.7% | +58.6% | +33.5% | -6.1% | +23.4% | +17.2% | +34.6% | -16.1% | |
| – | +20,613.3% | +29.9% | -45.6% | +29.7% | -7.9% | +3.2% | +43.2% | -1.0% | +14.0% | +4.6% | -4.3% | |
| – | -2.5% | -2.6% | -2.7% | +133.6% | -2.8% | -2.9% | -3.0% | -3.1% | -3.2% | -3.3% | -3.4% | |
| – | +25.3% | +8.1% | +68.2% | +11.4% | +9.8% | +3.8% | +2.6% | +22.8% | +9.7% | +6.1% | +13.9% | |
| – | +58.9% | +15.1% | +21.3% | +27.7% | +22.4% | +7.1% | +4.6% | +29.7% | +15.9% | +5.8% | +22.5% | |
| – | -5.9% | +47.0% | +3.4% | +4.3% | -3.6% | -36.8% | -17.4% | -74.8% | – | – | – | |
| – | +71.2% | +7.7% | +39.2% | +0.6% | +3.4% | +2.3% | -1.1% | +44.8% | -59.7% | +47.3% | +66.3% | |
| – | +0.4% | +0.4% | +139.1% | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | |
| – | -7.8% | +39.7% | -8.3% | -5.9% | -5.5% | +52.5% | -2.9% | +0.7% | +2.5% | +1.6% | -0.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.3% | +10.5% | +7.1% | +1.5% | +0.5% | +2.0% | +7.7% | +0.6% | +0.4% | +0.4% | +1.0% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.